Navigation Links
ULURU Inc. Reports First Quarter 2009 Financial Results

ADDISON, Texas, May 15 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE AMEX: ULU) today announced its financial results for the first quarter ended March 31, 2009. The Company reported a net loss of $3.1 million, or $0.05 per share, compared with a net loss of $1.8 million, or $0.03 per share, for the same period last year. At March 31, 2009, the Company held cash and cash equivalents of $5.1 million, compared with $7.6 million at December 31, 2009.

Commenting on the financial results Renaat Van den Hooff, President and CEO stated, "The increase in operating expenses continues to be driven by costs associated with our sales and marketing efforts for Altrazeal(TM) and the regulatory and clinical development costs of Altrazeal(TM) Silver and Altrazeal(TM) Collagen." Our recent accomplishments related to the Altrazeal(TM) wound care portfolio include:

  • The first published article on Altrazeal(TM) in human use appeared in "International Wound Journal," a peer-reviewed publication (Press release May 5, 2009)
  • There were 3 oral presentations and 20 posters published during the first four months of 2009 at several major Wound Care Conferences (DFCon, APWCA, and SAWC).
  • We obtained a temporary reimbursement (HCPCS) code for Altrazeal(TM).

Mr. Van den Hooff continued, "Despite the great clinical results we have experienced, we recognize that the selling cycle is taking longer than we originally expected. This has led us to refocus our sales strategy on specific sites of care. In parallel we have implemented cost improvement measures, including headcount reductions, in order to reduce our operating expenses moving forward. We are also continuing in our efforts to complete the acquisition of York Pharma plc. The strategic importance of creating a larger company with an established revenue base will enable ULURU to accelerate growth and position us to build shareholder value."

Operating Results

Revenue for the first quarter of 2009 was $169,000, compared to $256,000 for the first quarter of 2008. The decrease of approximately $87,000 in revenue from the first quarter of 2008 compared to the first quarter of 2009 was due to a $166,000 product order in 2008 for Aphthasol(R) that did not reoccur in 2009. This revenue decrease was partially offset by increases of $32,000 in Altrazeal product sales, $32,000 in sponsored research, $11,000 in OraDisc(TM) related licensing fees, and $4,000 in Zindaclin(R) royalties.

Research and development expenses for the first quarter of 2009 were $775,000, including $42,000 in share-based compensation, compared to $875,000, including $36,000 in share-based compensation, for the first quarter of 2008. The decrease of approximately $100,000 in research and development expenses was primarily due to lower development costs of $169,000 associated with our Altrazeal(TM) related wound care products and decreased costs of $10,000 associated with the clinical studies for Altrazeal(TM) and Altrazeal(TM) Silver. These decreases were partially offset by an increase in regulatory expenses of $88,000 associated with consultants engaged for our regulatory filings for Altrazeal(TM) related products.

Selling, general and administrative expenses for the first quarter of 2009 were $2.2 million, including $759,000 in share-based compensation, compared to $0.9 million, including $172,000 in share-based compensation, for the first quarter of 2008. The increase of approximately $1.3 million in selling, general and administrative expenses in 2009 was primarily due to costs associated with our sales and marketing efforts of approximately $600,000, distribution services of approximately $120,000, and a net increase of approximately $458,000 in compensation costs. The net increase in compensation cost includes approximately $519,000 of share-based compensation expense after giving effect to certain vesting accelerations of stock options and restricted stock which were partially offset by certain stock option forfeitures and by savings of $77,000 relating to benefit forfeitures pursuant to the Separation Agreement with our former chief executive officer. Other factors affecting the cost increase were additional expenses of $82,000 for legal services associated with our patent filings and $70,000 for legal expense associated with SEC filings, employment matters, and trademark filings.

Interest and miscellaneous income for the first quarter of 2009 was $15,000 as compared to $125,000 for the first quarter of 2008. The decrease of approximately $110,000 is attributable to a decrease in interest income due to lower cash balances and interest yields in 2009.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex(TM) Aggregate technology and OraDisc(TM) transmucosal delivery system. For further information about ULURU Inc., please visit our website at For further information about Altrazeal(TM), please visit our website at

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to future financial performance of ULURU Inc. (the "Company"), development of a silver containing product, the expected publication of articles and posters, the effect of cost-savings programs, the launch of additional products, and the proposed acquisition of York Pharma, plc. When used in this press release, the words "may," "targets," "goal," "could," "should," "would," "believe," "feel," "expects," "confident," "anticipate," "estimate," "intend," "plan," "potential" and similar expressions may be indicative of forward-looking statements including without limitation statements relating to the progress of our technology, clinical and regulatory results for our products, advantages of our products, and the benefits of the York Pharma plc acquisition. These statements by their nature involve substantial risks and uncertainties, certain of which are beyond the Company's control. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of an unanticipated event. Further, management cannot assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and other reports filed by us with the Securities and Exchange Commission.

    Contact: Company
    Renaat Van den Hooff
    President & CEO
    Terry K. Wallberg
    Vice President & CFO
    (214) 905-5145

                                ULURU Inc.
                            SUMMARY OF RESULTS
                       STATEMENTS OF OPERATIONS DATA

                                              Three Months Ended
                                                   March 31,
                                             2009            2008
      License fees                         $24,651         $13,771
      Royalty income                        79,245          75,574
      Product sales                         32,643         166,473
      Other                                 32,190             ---
      Total Revenues                       168,729         255,818

      Cost of goods sold                     6,077         137,614
      Research and development             775,418         875,216
      Selling, general and
       administrative                    2,224,619         893,235
      Amortization                         266,267         269,185
      Depreciation                          32,571          20,272
      Total Costs and Expenses           3,304,952       2,195,522

    OPERATING (LOSS)                    (3,136,223)     (1,939,704)

    Other Income (Expense)
      Interest and miscellaneous
       income                               14,554         125,045
      Interest expense                         ---             ---

    (LOSS) BEFORE INCOME TAXES          (3,121,669)     (1,814,659)

      Income taxes                             ---             ---
    NET (LOSS)                         $(3,121,669)    $(1,814,659)

    Basic and diluted net (loss)
     per common share                       $(0.05)         $(0.03)

     COMMON SHARES OUTSTANDING          65,525,288      62,429,586

                                 ULURU Inc.

                                          March 31,    December 31,
                                            2009          2008
                                         (Unaudited)    (Audited)

    Cash and cash equivalents            $5,139,376    $7,567,588
    Current assets                        6,796,935     9,312,041
    Property and equipment, net           1,791,380     1,828,040
    Other assets                          9,723,287     9,985,988
    Total assets                         18,311,602    21,126,069

    Current liabilities                   1,773,852     2,243,113
    Long term liabilities - deferred
     revenue                              1,331,875     1,356,526
    Total liabilities                     3,105,727     3,599,639
    Total stockholders' equity           15,205,875    17,526,430

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2009 and to Provide a Business Update
2. ULURU Inc. Announces Altrazeal(TM) Clinical Experience Published in the International Wound Journal
3. ULURU Inc. Signs Offer Letter to Acquire York Pharma plc
4. ULURU Inc. (ULURU) Dealing Disclosure Requirements
5. ULURU Inc. Reports Financial Results for Fourth Quarter and Year Ended December 31, 2008
6. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2008 and to Provide a Business Update
7. ULURU Inc. Announces Appointment of Jeffrey A. Niezgoda, M.D., as Chairman of Scientific Advisory Board
8. ULURU Inc. Announces Senior Management Change
9. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2008 and to Provide a Business Update
10. ULURU Inc. Announces the Launch of the Altrazeal(TM) Website
11. ULURU Inc. Hosts Symposium on Altrazeal(TM) at the 23rd Annual Clinical Symposium on Advances in Skin & Wound Care
Post Your Comments:
(Date:11/25/2015)... ... 2015 , ... Beddit® has launched a new Android app for ... features a more intuitive SleepScore™ that rates sleep quality on a 100-point scale and ... created by a proprietary algorithm. Beddit analyzes the data to provide an easy to ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... In an ... Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of ... and surgical intensive care units (totaling 30 beds) from May 2014 through October 2015 ...
(Date:11/25/2015)... ... ... Today, Mothers Against Drunk Driving (MADD) learned that the number of ... time since 2011. In 2014, there were 9,967 fatalities involving an alcohol impaired driver, ... Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in 2014. Drunk ...
(Date:11/25/2015)... Silver Spring, Md (PRWEB) , ... November 25, ... ... the Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups ... the history of this disease. The Periwinkle Pioneers, nominated by the public, will ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... announced that it has undertaken significant expansion of its current state of the ... is part of PharmaTech’s strategy to increase its manufacturing capacity as well as ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 3D ... by 2022, according to a new report by Grand View ... Kidney Disease (CKD) which demands kidney transplantation is expected to ... cost effective substitute for organ transplantation. --> 3D ... by 2022, according to a new report by Grand View ...
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
Breaking Medicine Technology: